AL-102 is a Small Molecule owned by Ayala Pharmaceuticals, and is involved in 3 clinical trials, of which 2 are ongoing, and 1 is planned.

BMS-986115 (AL-102) acts by inhibiting gamma-secretase. Gamma secretase plays a major role in the activation of Notch signalling pathway that is responsible for the progression of cancer and in increased production of B-cell maturation antigen (BCMA). The drug candidate binds to GS and blocks the proteolytic activation of Notch receptors and decrease the BCMA leading to the induction of apoptosis in tumor cells.

The revenue for AL-102 is expected to reach a total of $678m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the AL-102 NPV Report.

AL-102 was originated by Bristol-Myers Squibb and is currently owned by Ayala Pharmaceuticals.

AL-102 Overview

BMS-986115 (AL-102) is under development for the treatment of desmoid tumors, relapsed and refractory T-cell acute lymphoblastic leukemia (T-ALL) and relapsed/refractory multiple myeloma. It is administered orally. The drug candidate is a pan-notch gamma secretase inhibitor.

It was under development for the treatment of advanced solid tumors

Ayala Pharmaceuticals Overview

Ayala Pharmaceuticals is a clinical-stage bio-pharmaceutical company which develops novel drugs for defined cancers. Its lead product candidate AL101 and AL102 to treat cancers. The products render different cancers like desmoid tumors, adenoid cystic carcinoma (ACC), triple negative breast cancer (TNBC) and T-cell acute lymphoblastic leukemia (T-ALL). Ayala Pharmaceuticals desmoid tumors arise in upper and lower extremities, abdominal wall, head and neck area, mesenteric root and chest wall of the body. In addition, it also focuses on inhibiting the Notch activating pathway with best-in-class gamma secretase inhibitors (GSIs). The company has operations in Israel and the US. Ayala Pharmaceuticals is headquartered in Wilmington, Delaware, the US.

The company reported revenues of (US Dollars) US$3.5 million for the fiscal year ended December 2021 (FY2021), a decrease of 5.4% over FY2020. The operating loss of the company was US$39.2 million in FY2021, compared to an operating loss of US$29.8 million in FY2020. The net loss of the company was US$40.3 million in FY2021, compared to a net loss of US$30.2 million in FY2020.

Quick View – AL-102

Report Segments
  • Innovator
Drug Name
  • AL-102
Administration Pathway
  • Oral
Therapeutic Areas
  • Non Malignant Disorders
  • Oncology
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.